Ethanol administration (2 g/kg i.p.) to fasted male Wistar rats caused, on average, a 64% decrease in the cytosolic free NAD+:NADH ratio and a 41% decrease in the mitochondrial free NAD+:NADH ratio measured 90 min after ethanol was injected. Treatment of animals with either Naloxone (2 mg/kg i.p.) 1 hr after ethanol or 3-palmitoyl-(+)-catechin (100 mg/kg p.o. 1 hr before ethanol) prevented these ethanol induced redox state changes, without affecting the ethanol elimination rate or the hepatic acetaldehyde concentration measured at 90 min after ethanol administration. The thiol compounds cysteine and malotilate (diisopropyl-1,3-dithiol-2-ylidene malonic acid) significantly lowered the hepatic acetaldehyde concentrations measured at 0.75, 1.5 and 6.0 hr after ethanol, and caused a 29% and 12% increase respectively in the ethanol elimination rate, without affecting the ethanol induced alterations in the NAD+:NADH ratio. Pretreatment of animals with the aldehyde dehydrogenase inhibitor, cyanamide (1 mg/kg or 15 mg/kg p.o. one hour before ethanol), caused increases of up to 23-fold in the hepatic acetaldehyde level, without influencing the cytosolic NAD+:NADH ratio in ethanol dosed rats, while significantly reducing the ethanol elimination rate by up to 44%, compared with controls. These results suggest that ethanol oxidation by cytosolic alcohol dehydrogenase may be regulated in part by the hepatic acetaldehyde concentration achieved during ethanol metabolism rather than NADH reoxidation, either to supply NAD for the dehydrogenase, or to reduce inhibition of the enzyme by NADH, being a rate-limiting factor in ethanol metabolism in fasted rats.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0006-2952(85)90736-1DOI Listing

Publication Analysis

Top Keywords

hepatic acetaldehyde
20
ethanol
17
ethanol elimination
16
elimination rate
16
nad+nadh ratio
16
acetaldehyde concentration
12
redox state
8
fasted rats
8
ethanol administration
8
free nad+nadh
8

Similar Publications

Post-COVID metabolic enzyme alterations in K18-hACE2 mice exacerbate alcohol-induced liver injury through transcriptional regulation.

Free Radic Biol Med

January 2025

Korea Mouse Phenotyping Center, Seoul National University, Seoul, 08826, Republic of Korea; Laboratory of Developmental Biology and Genomics, Research Institute for Veterinary Science, and BK21 PLUS, Program for Creative Veterinary Science Research, College of Veterinary Medicine, Seoul National University, Seoul, 08826, Republic of Korea; Interdisciplinary Program for Bioinformatics, Program for Cancer Biology and BIO-MAX/N-Bio Institute, Seoul National University, Seoul, 08826, Republic of Korea. Electronic address:

Article Synopsis
  • COVID-19, caused by SARS-CoV-2, poses serious global health risks, including the potential for secondary liver injury related to metabolic enzyme changes.
  • This study explores how prior infection with SARS-CoV-2 affects alcohol-induced liver damage, using transgenic mice that express human ACE2.
  • Results showed that infected mice experienced worsened liver injury after alcohol consumption, with alterations in metabolic enzymes and increased levels of a toxic alcohol byproduct, indicating a complex interaction between COVID-19 and alcohol effects on the liver.
View Article and Find Full Text PDF

Elucidating the Phase I metabolism of psilocin in vitro.

Arch Toxicol

January 2025

Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore.

Psilocin is a well-studied controlled substance with potential psychotherapeutic applications. However, research gaps remain regarding its metabolism. Our objective was to elucidate a comprehensive Phase I metabolic profile of psilocin to support its forensic management and clinical development.

View Article and Find Full Text PDF

Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function.

World J Gastroenterol

November 2024

Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.

Article Synopsis
  • The article by Koizumi examines therapeutic targets for fibrosis in alcohol-related liver disease (ALD) and highlights elafibranor (EFN) as a dual agonist for PPARα and PPARδ.
  • EFN, currently in phase III trials for other liver diseases, shows promise in reducing hepatic steatosis and fibrosis in ALD by activating PPARα and promoting fat metabolism.
  • Additionally, EFN improves the gut-liver axis and intestinal barrier function, alleviating inflammation and contributing to overall liver health.
View Article and Find Full Text PDF

Protective Effect and Mechanism of L-Theanine on Acute Alcoholic Liver Injury in Mice.

Mol Nutr Food Res

December 2024

Key Lab of Tea Science of Ministry of, Education, Hunan Agricultural University, Changsha, Hunan, 410128, China.

Scope: Acute alcoholic liver injury (AALI), a global health concern, is exacerbated by excessive episodic drinking. L-theanine (LTA), a compound found in tea leaves, mitigates the AALI-induced liver oxidative stress and inflammation. However, its relationship with alcohol metabolism and its liver-protective mechanism remains unexplored.

View Article and Find Full Text PDF

Alcohol liver disease has become a worldwide critical health problem. The ingested alcohol could be converted into acetaldehyde or combined with free fatty acids to induce the endoplasmic reticulum oxidative stress in the liver. Coincidentally, AKR7A5 has both aldehyde detoxification and antioxidant effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!